Repurposing COVID-19 Compounds (via MMV COVID Box): Almitrine and Bortezomib Induce Programmed Cell Death in Trypanosoma cruzi
Pathogens · 2025
DOI: 10.3390/pathogens14020127 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathogens, 2025. Verfasst von Carlos J Bethencourt-Estrella und 3 weiteren Autor:innen. Beteiligte Einrichtung: Instituto Universitario de Enfermedades Tropicales y Salud Pública de Canarias, Universidad de La Laguna, Avda. Astrofísico Fco. Sánchez, S/N, 38203 …. Hauptthemen laut MEDLINE: Drug Repositioning, Trypanosoma cruzi, Trypanocidal Agents, Bortezomib. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Centro de Investigación Biomédica en Red, Cabildo de Tenerife, Fundación CajaCanarias.
Abstract (Originalsprache)
Chagas disease, caused by the protozoan Trypanosoma cruzi, affects millions globally, with limited treatment options available. Current therapies, such as benznidazole and nifurtimox, present challenges, including their toxicity, side effects, and inefficacy in the chronic phase. This study explores the potential of drug repurposing as a strategy to identify new treatments for T. cruzi, focusing on compounds from the Medicines for Malaria Venture (MMV) COVID Box. An initial screening of 160 compounds identified eight with trypanocidal activity, with almitrine and bortezomib showing the highest efficacy. Both compounds demonstrated significant activity against the epimastigote and amastigote stages of the parasite and showed no cytotoxicity in murine macrophage cells. Key features of programmed cell death (PCD), such as chromatin condensation, mitochondrial membrane potential disruption, and reactive oxygen species accumulation, were observed in T. cruzi treated with these compounds. The potential to induce controlled cell death of these two compounds in T. cruzi suggests they are promising candidates for further research. This study reinforces drug repurposing as a viable approach to discovering novel treatments for neglected tropical diseases like Chagas disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Instituto Universitario de Enfermedades Tropicales y Salud Pública de Canarias, Universidad de La Laguna, Avda. Astrofísico Fco. Sánchez, S/N, 38203 La Laguna, Spain.
- Departamento de Obstetricia y Ginecología, Pediatría, Medicina Preventiva y Salud Pública, Toxicología, Medicina Legal y Forense y Parasitología, Universidad de La Laguna, 38203 La Laguna, Spain.
- Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, 28220 Madrid, Spain.
ORCID-Profile: Atteneri López-Arencibia
Förderung
- Centro de Investigación Biomédica en Red
- Cabildo de Tenerife
- Fundación CajaCanarias
- Instituto de Salud Carlos III
- Consorcio Centro de Investigación Biomédica (CIBER) de Enfermedades Infecciosas (CIBERINFEC)
- Instituto de Salud Carlos III, 28006 Madrid, Spain
- Cabildo Insular de Tenerife 2023–2028
- Ministerio de Sanidad, Spain
Zitieren
APA
Bethencourt-Estrella, C. J., López-Arencibia, A., Lorenzo-Morales, J., & Piñero, J. E. (2025). Repurposing COVID-19 Compounds (via MMV COVID Box): Almitrine and Bortezomib Induce Programmed Cell Death in Trypanosoma cruzi. Pathogens. https://doi.org/10.3390/pathogens14020127
Vancouver
Bethencourt-Estrella CJ, López-Arencibia A, Lorenzo-Morales J, Piñero JE. Repurposing COVID-19 Compounds (via MMV COVID Box): Almitrine and Bortezomib Induce Programmed Cell Death in Trypanosoma cruzi. Pathogens. 2025. doi:10.3390/pathogens14020127
BibTeX
@article{BethencourtEstrella2025,
author = {Bethencourt-Estrella, Carlos J and López-Arencibia, Atteneri and Lorenzo-Morales, Jacob and Piñero, José E},
title = {Repurposing COVID-19 Compounds (via MMV COVID Box): Almitrine and Bortezomib Induce Programmed Cell Death in Trypanosoma cruzi},
journal = {Pathogens},
year = {2025},
doi = {10.3390/pathogens14020127}
}
EUVIMED